Key result
Small-molecule inhibitor eliminates bent HCV RNA trajectory, providing a structural mechanism for antiviral activity.
Why the study?
The structural mechanism by which small-molecule inhibitors affect the HCV IRES domain IIa RNA to inhibit viral replication was not fully understood.
The study provides a structural mechanism for the antiviral activity of a small-molecule inhibitor class targeting the HCV IRES domain IIa RNA.
No takes yet. Share an insight, caveat, or question.
Does not alter HCV therapy; leaves open whether IRES-targeted inhibitors achieve clinical efficacy.
Paulsen et al. (2010) studied Hepatitis C virus (HCV). Small-molecule inhibitor of HCV replication was evaluated on Binding affinity and structural conformational change. Binding of a small-molecule inhibitor to the HCV IRES domain IIa RNA eliminates the bent RNA helical trajectory, providing a structural mechanism for its antiviral activity.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: